Novartis Receives FDA Approval for Rhapsido to Treat Symptomatic Dermographism
MT newswire2026/10/07 16:3312:33 PM EDT, 10/07/2026 (MT Newswires) -- Novartis (NVS) said Wednesday the US Food and Drug Administration approved Rhapsido for adults with symptomatic dermographism inadequately controlled by H1 antihistamines. Symptomatic dermographism is a form of chronic inducible urticaria in which hives and itching can be triggered by skin friction, scratching or rubbing. In the phase III RemIND trial, 29.3% of patients treated with Rhapsido achieved a complete response from hives at week 12, compared with 14.0% for placebo, Novartis said. Rhapsido is now approved in the US for both symptomatic dermographism and chronic spontaneous urticaria, Novartis said. Novartis shares were 2.3% higher in Wednesday trading. Price: 143.95, Change: +3.16, Percent Change: +2.24
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
SNT Holdings, Related Party Raise Combined Stake in SNTEnergy to 55.75% From 52.75%
Cold wave and rising fuel costs drive electricity prices in northeastern Japan and Tokyo to a four-year high
Japan's spot electricity prices surged to multi-year highs over the weekend.
Google (GOOGL.US) warns that new Australian cybersecurity regulations may cut off minors' access to Gmail
Google stated that a new cybersecurity bill in Australia could prevent minors from using Gmail.
Canaccord Genuity: Lowers Oklo's target price to $66
Crypto prices
More
